Abstract. Pigs are increasingly being recognized as good large-animal models for translational research, linking basic science to clinical applications in order to establish novel therapeutics. This article reviews the current status and future prospects of genetically modified and cloned pigs in translational studies. It also highlights pigs specially designed as disease models, for xenotransplantation or to carry cell marker genes. Finally, use of porcine somatic stem and progenitor cells in preclinical studies of cell transplantation therapy is also discussed. Key words: Cloned pig, Gene knockout, Transgenic pig, Translational research (J. Reprod. Dev. 55: [225][226][227][228][229][230] 2009) t present, pigs are not only considered important livestock but are also essential large-animal models in various types of biomedical research [1] [2] [3] [4] [5] [6] . Furthermore, due to recent technological advances in genetic modification and somatic cell cloning, the range of applications for porcine models has increased markedly [7] [8] [9] [10] [11] [12] [13] [14] . The present review focuses on development of genetically modified and cloned pigs and their use in translational studies.
t present, pigs are not only considered important livestock but are also essential large-animal models in various types of biomedical research [1] [2] [3] [4] [5] [6] . Furthermore, due to recent technological advances in genetic modification and somatic cell cloning, the range of applications for porcine models has increased markedly [7] [8] [9] [10] [11] [12] [13] [14] . The present review focuses on development of genetically modified and cloned pigs and their use in translational studies.
Translational research plays an important role as a bridge between basic science outcomes and the clinical realm, leading to development of novel therapeutics. However, disparate findings for rodent models and humans have hindered the translation of rodent data into actionable technologies for patients [15] . In contrast, pigs have many anatomical and physiological similarities to humans, including their cardiovascular systems, omnivorous gastrointestinal tracts and central nervous systems. Their physical sizes are also more comparable to that of humans, rendering pigs more appropriate for development of new surgical or endoscopic techniques.
In the future, more advanced translational research may be conducted by improving the clinical relevance of pig models through genetic engineering. This article reviews the current status and future prospects of genetically modified pigs in preclinical studies of stem and progenitor cell therapy, the development of disease models and xenotransplantation.
Development of Disease Models and Their Use in Stem Cell Transplantation
Pigs are recognized as excellent disease models in a variety of areas, including nutrition, toxicology, dermatology, diabetes, cancer, eye diseases, cardiovascular diseases, degenerative joint diseases and skeletal growth.
Petters et al. [16] pioneered the development of transgenic pigs as disease models by establishing a porcine retinitis pigmentosa (RP) model. By expressing a mutant rhodopsin gene, pigs with retinal cone cell regression comparable to that of RP patients were produced. These RP disease models have been used in several subsequent studies [17] .
The cystic fibrosis (CF) model pig [18, 19] is a revolutionary tool for research on the pathology and therapy of this hereditary disease. CF is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR). CF mice with targeted CFTR gene mutations fail to develop pulmonary and pancreatic symptoms, the leading causes of morbidity and mortality in CF patients [20, 21] . The development of a model CF pig may help to overcome these translational problems.
Diabetes mellitus, characterized by high blood glucose levels and complications such as diabetic retinopathy, diabetic nephropathy and diabetic neuropathy, is one of the most serious chronic diseases in modern society [22] . Umeyama et al. [23] developed transgenic-cloned pigs carrying a mutant human hepatocyte nuclear factor (HNF)-1α gene known to cause maturity-onset diabetes of the young type 3 (MODY3). These pigs manifested the pathophysiology of diabetes, such as a high nonfasting blood glucose level (>200 mg/dl), a significant increase in blood glucose level after glucose loading, abnormal formation of Langerhans islets and poor insulin secretion. Thus, expression of dominantnegative human mutant transgenes in pigs may open new avenues for generating porcine models of other diseases [24] .
Other than the aforementioned examples, the use of transgenic pigs as disease models has been very limited [24] [25] [26] . This may be due to the specialized requirements of disease models and the relatively underdeveloped methods of producing transgenic pigs as compared with the well-characterized genetic modification of rodents. However, with the recent development of such innovative methods as intracytoplasmic sperm injection (ICSI)-mediated gene transfer [27, 28] and somatic cell nuclear transfer (SCNT) [9] [10] [11] [12] , it may now be easier to design specific disease-model pigs. Dilated cardiomyopathy and Parkinson's disease are two conditions that could benefit from development of these models.
Stem and progenitor cell therapy appears promising for treatment of various seemingly intractable diseases [29] [30] [31] [32] . Grafts of a relatively small number of cells have been shown to elicit symptom improvement in rodents [33] . However, in human clinical applications, it is necessary to culture a much higher number of graft cells. Therefore, larger animals such as pigs may be instrumental in obtaining clinically relevant data.
In recent years, researchers have actively sought to establish porcine somatic stem cell lines. To date, bone marrow-derived stem/progenitor cells [34] [35] [36] [37] [38] [39] [40] [41] , liver progenitor cells [42] , salivary gland progenitor (SGP) cells [43] , retinal stem/progenitor cells [44] , adipose tissue-derived stem/progenitor cells [45, 46] and additional cell types [47] [48] [49] [50] [51] [52] have been established. According to Matsumoto et al. [43] , endodermal SGP cells are capable of differentiating into islet cells and hepatocytes, making these cells extremely useful for research on stem and progenitor cell therapies. In addition, porcine endodermal SGP cells may be suitable as nuclear donor cells in somatic cell cloning [53, 54] .
Using somatic cell cloning technology, it is possible to develop a syngeneic donor-recipient system in pigs, as shown in Fig. 1 . Use of syngeneic pig models capable of avoiding rejection reactions will markedly advance research on stem and progenitor cell therapies.
Furthermore, use of cells labeled with fluorescent protein markers will enable more efficient monitoring after transplantation.
Development of Transgenic Pigs with Reporter Genes
Genetically engineered animals including cell markers, such as fluorescent proteins, are highly useful in research that requires tracking of transplanted cells or tissues [55] [56] [57] [58] . In rodents, transgenic animals expressing such cell markers as green fluorescent protein (GFP), red fluorescent protein (RFP) and β-galactosidase have been produced, making rodents useful in a wide range of research [57, [59] [60] [61] [62] [63] . In addition, transgenic mice harboring a fluorescent ubiquitination-based cell-cycle indicator (Fucci) have recently been developed [64] . These mice are expected to foster understanding of how the cell cycle is coordinated with various biological events [64] .
Transgenic pigs expressing fluorescent cell markers have been generated by many research groups [7, 8, 27, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] . For example, Webster et al. [72] produced transgenic pigs that simultaneously expressed red fluorescent protein from Discosoma (DsRed), enhanced GFP (EGFP) and enhanced blue fluorescent protein (EBFP). However, the effect of using DsRed, which is highly cytotoxic [62] , in transgenic pigs has not been clarified. Matsunari et al. [14] produced transgenic-cloned pigs carrying the humanized Kusabira-Orange (huKO) gene, a newly developed red fluorescent protein. Kusabira-Orange, which was cloned from the coral stone Fungia concinna (Kusabira-Ishi in Japanese), yields an orange-red fluorescence in its dimeric form with excitation/emission maxima of 558/583 nm [77] . Fluorescent proteins with excitation/emission spectra in red or far-red wavelengths, such as DsRed or KusabiraOrange, have such attractive features as low background autofluorescence [60, 78] . This low autofluorescence has been demonstrated in the liver and lungs of huKO transgenic pigs [14] , despite the fact that these organs are known to have strong autofluorescence in EGFP-transgenic animals [60, 78] . Furthermore, the clear red fluorescence of the huKO protein is maintained in paraffin-embedded tissue sections [14] .
In huKO transgenic-cloned pigs, systemic red fluorescent protein expression has been confirmed by analysis of 23 tissues and organs, including the brain, eyes, internal organs, reproductive tracts, skeletal muscle, bone, skin and hooves [14] . Fluorescence has also been confirmed in the pigs stem/progenitor cells, including mesenchymal stem cells, neuronal and pancreatic progenitor cells and salivary gland-derived endodermal progenitor cells (unpublished data). In addition, huKO transgenic-cloned pigs demonstrate normal growth and reproductive ability.
As shown in [7, 67, 69] , sperm-mediated gene-transfer (SMGT) [72, 73] and ICSI-mediated gene transfer [27, 70, 74] . Each method is accompanied by various considerations. SCNT has been used most commonly in the production of transgenic pigs carrying fluorescent protein markers (Table 1) , although Park et al. [65] reported that SCNT results in mosaic expression of the transgene, probably due to epigenetic modification of gene expression. In using viral vectors to produce transgenic animals, it is important to consider gene silencing [80] , which may influence the cell or tissue type in which the transduced gene is expressed. SMGT [81] requires special experimental conditions, such as the use of particular boar sperm, to generate reproducible results [82, 83] . Meanwhile, ICSI-mediated gene transfer [27] allows efficient introduction of transgenes into pig oocytes, although the techniques and optimal conditions for gene transfer need to be further investigated [28] .
The commonly used SCNT approach allows concurrent production of transgenic animals expressing a marker gene and nontransgenic clone-siblings from the same nuclear donor cells (Fig.  1) . These cloned animals could provide a useful model for donors and recipients of syngeneic background. However, the immunogenicity of fluorescent proteins may hamper long-term tracking of cells and tissues in transplantation experiments [61] . In contrast, β-galactosidase is less immunogenic than fluorescent protein [61] and may thus be a better candidate for transplantation studies. In future development of cell marker-transgenic pigs, it will be very important to consider the immunogenicity and visibility of marker gene products.
Development of Genetically Modified Pigs for Xenotransplantation Research
In the field of organ transplantation, the donor shortage is a persistent problem worldwide. One proposed solution to this problem is xenotransplantation, in which non-human animal organs are transplanted into human patients. Research is currently being conducted to enable clinical implementation of this method, which will likely use pigs as organ donors for a variety of reasons [1, [84] [85] [86] .
In order to accomplish effective xenotransplantation between pigs and humans, organ rejection must be overcome. Xenograft rejection comprises several steps, including hyperacute rejection, delayed xenograft rejection and cellular rejection [86] . To overcome these rejection reactions, multilayered genetic modification is required [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] . In other words, the complex mechanisms of xenograft rejection [91, 92, 100] must be countered by multiple gene modifications.
One way to produce pigs with multiple genetic modifications is to cross multiple lines of transgenic pigs. However, this method requires a great deal of time and effort, especially due to the long life cycle of pigs. A simpler method is based on SCNT, making more complex genetic modifications possible by introducing genes into cultured cells [9] [10] [11] [12] 101] . In fact, by knocking out the α1,3-galactosyltransferase (α1,3GalT) gene in the cells of pigs with multiple transgenes, knockout (KO)-transgenic pigs may be generated [102, 103] . Another advantage of SCNT is that additional genetic modifications may be added based on analysis of the first genetically modified pigs' phenotypes.
Using the above-mentioned approaches, pigs with highly sophisticated genetic modifications, including polytransgenic and α1,3GalT-KO pigs, have been produced, but they are far from optimal [86, [104] [105] [106] [107] . In the future, breeding among multiple existing transgenic lines and introducing additional new genes by SCNT may be used in combination [103, 108] to improve outcomes. These kinds of multiple gene modifications mean that the ability to perform serial cloning (multi-generational cloning) would have important implications (Fig. 2 ) [54, 109] . Therefore, we are producing pigs for xenotransplantation and pursuing the possibility of serial pig cloning. In serial cloning, accumulation of epigenetic modifications was initially thought to make it impossible to clone past several repetitions [110, 111] . However, with recent advances in SCNT, it may be possible to repair epigenetic modifications by chemical treatment [112] [113] [114] [115] [116] [117] [118] . Thus, somatic cell cloning may be repeated beyond previously expected limits (Wakayama, personal communication) . Future research should focus on improving the health and production efficiency of these somatic cell porcine clones. 
